|
AstraZeneca PLC on Monday announced positive high-level results from its Neuro-TTRansform phase III trial for eplontersen, while Enhertu received another approval in Japan. The trial explored the treatment for use in hereditary transthyretin-mediated amyloid polyneuropathy. ‘At 66 weeks, patients treated with eplontersen continued to demonstrate a statistically significant and clinically meaningful change from baseline versus an external placebo group,’ the Cambridge-based pharmaceutical company said. The results are consistent with previous findings published in June, which showed positive 35-week findings. Mene Pangalos, executive vice president of AstraZeneca’s BioPharmaceuticals research & development unit, said: ‘These results further underscore eplontersen‘
|
